Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

BACKGROUND: PCSK9 inhibitor therapy has been approved by the FDA as an adjunct to diet-maximal tolerated cholesterol lowering drug therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) with suboptimal LDL cholesterol (LDL...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lipids Health Dis
Hauptverfasser: Shah, Parth, Glueck, Charles J., Jetty, Vybhav, Goldenberg, Naila, Rothschild, Matan, Riaz, Rashid, Duhon, Gregory, Wang, Ping
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991071/
https://ncbi.nlm.nih.gov/pubmed/27538393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12944-016-0302-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge